Global $13.8 Billion Antimicrobial Resistance Market, 2027 | Opportunity Breakdown by Disease, Pathogen, Drug Class, End-user and Region - ResearchAndMarkets.com
Retrieved on:
Monday, September 27, 2021
Biotechnology, Pharmaceutical, Health, Infection, Ceftolozane/tazobactam, DDD, Subclinical infection, Research, Vaccine, WHO, Health, CAGR, University, Overalls, ABSSSI, Mind, Patient, Cephalosporin, AMR, Lipoglycopeptide, Physician, 2-Oxazolidone, Clifton Springs Hospital & Clinic, Tetracycline, National Rural Development Partnership, One Health, Public health, Death, Merck, Local government, Gaps, Allergan, Heel, Growth, CDI, Melinta Therapeutics, Contract, COVID-19, Philippe Ciais, IDSA, Achilles, Ceftazidime/avibactam, Tuberculosis verrucosa cutis, Meropenem/vaborbactam, Electronic Healthcare Network Accreditation Commission, BSI, BAA, OECD, Investment, Government, Frazier Healthcare Partners, US, Contract research organization, Antibiotics, Pharmaceutical industry
The global antimicrobial resistance market was valued at US$ 9.39 billion in 2020, and is estimated to reach US$ 13.8 billion in 2027, with a CAGR of 4.68% from 2021-2027.
Key Points:
- The global antimicrobial resistance market was valued at US$ 9.39 billion in 2020, and is estimated to reach US$ 13.8 billion in 2027, with a CAGR of 4.68% from 2021-2027.
- The emergence and spread of drug-resistant pathogens which have acquired new resistance mechanisms, leading to antimicrobial resistance, continues to threaten our ability to treat common infections.
- New antibacterial are urgently needed - for instance, to treat carbapenem-resistant gram-negative bacterial infections as identified in the WHO priority pathogen list.
- Europe was the second largest regional market in the global arena in 2020, supported largely by growing number of antibiotic-resistant infections.